AtaiBeckley Conference Call Summary Company Overview - **Company**: AtaiBeckley (NasdaqGM: ATAI) - **Focus**: Mental health conditions, particularly treatment-resistant depression (TRD) and social anxiety disorder (SAD) [2][3] Key Assets in Development 1. **BPL-003**: - **Type**: Intranasal formulation of mebufotenin (5-methoxy-DMT) - **Indication**: Treatment-resistant depression - **Phase**: Advanced, Phase 2b - **Efficacy**: - 8 mg dose showed superior efficacy compared to 12 mg in a Phase 2b study, with a 6.2-point change on the MADRS score compared to placebo [10][11][12][18] - Comparable efficacy to SPRAVATO with only one dose required [11][12] - Open label extension showed continued improvement and remission rates of about 80% [28][29] 2. **VLS-01**: - **Type**: Oral thin film formulation of DMT - **Indication**: Treatment-resistant depression - **Phase**: Phase 2b, currently ongoing with results expected in the second half of the year [133][153] 3. **EMP-01**: - **Type**: R-enantiomer of MDMA - **Indication**: Social anxiety disorder - **Phase**: Phase 2A, exploratory study showed comparable effects to SSRIs at 6 weeks [168][179] Mechanism of Action - **Psychedelic Compounds**: - All three assets are psychedelics that promote neuroplasticity and alter dysregulated circuits associated with depression and anxiety [8][9] - BPL-003 and VLS-01 are designed for short-duration effects, allowing for rapid patient discharge [31][32] Market Landscape - **Interventional Psychiatry**: - A shift from traditional psychiatry to interventional methods, emphasizing rapid symptom relief [222][226] - SPRAVATO has set a precedent in this space, generating approximately $1.7 billion in revenue last year, with expectations of $3 billion this year [240][241] Competitive Advantage - **Convenience**: - AtaiBeckley's products are designed for shorter treatment durations compared to existing options like SPRAVATO, which requires weekly dosing [252][259] - KOLs (Key Opinion Leaders) suggest a strong preference for AtaiBeckley's products due to reduced time commitment for patients [252][259] Infrastructure and Economics - **Current Treatment Sites**: - Approximately 5,000 to 6,000 sites in the U.S. are equipped to administer treatments, with around 600 sites responsible for 80% of revenue [270][272] - **Economic Model**: - AtaiBeckley aims to optimize clinic operations by allowing multiple patients to be treated in a day, enhancing revenue potential for treatment sites [346][348] Future Outlook - **Regulatory Path**: - Plans for two Phase 3 trials for BPL-003, with a focus on flexibility in dosing for physicians [75][76] - **Market Potential**: - The treatment-resistant depression market is estimated at around 3 million people, with current treatments only reaching about 3% of this population [309][311] Conclusion - AtaiBeckley is positioned to capitalize on the growing field of psychedelics in mental health treatment, with a strong pipeline of products that offer convenience and efficacy compared to existing therapies. The company is focused on addressing significant unmet needs in mental health, particularly in treatment-resistant depression and social anxiety disorder.

Core Insights - AtaiBeckley Inc. is advancing its clinical-stage biotechnology efforts, particularly focusing on BPL-003, a nasal spray for treatment-resistant depression (TRD), with plans to initiate Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA [1][4][5] Clinical Development - BPL-003 has received Breakthrough Therapy Designation and has shown positive Phase 2b results, indicating rapid antidepressant effects by Day 2 and sustained improvements for up to eight weeks [2][8] - The upcoming Phase 3 studies, ReConnection-1 and ReConnection-2, will consist of a 12-week randomized, double-blind, placebo-controlled core study, followed by a 52-week open-label extension [4][5] Financial and Operational Readiness - The company has reaffirmed its cash runway extending into early 2029, ensuring financial stability for ongoing and future clinical trials [3][7] - AtaiBeckley is advancing its commercial readiness strategy for BPL-003, aiming to integrate the treatment into existing psychiatric workflows without the need for in-session psychotherapy [5][6] Pipeline Progress - The company is also making progress with other pipeline candidates, including positive Phase 2a results for EMP-01 and anticipates topline data for VLS-01 in H2 2026 [3][7] Expert Perspectives - Discussions during the Investor Day highlighted the importance of streamlined treatment experiences and the potential for BPL-003 to expand patient access while maintaining clinical efficacy [9][10]

Core Viewpoint - HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical, enhancing its interventional psychiatry network on Florida's west coast, with Dura being revenue-generating and EBITDA positive [1][9]. Company Overview - HOPE Therapeutics is focused on developing a network of interventional psychiatry clinics that utilize psychedelic medications, including ketamine and Spravato®, combined with Transcranial Magnetic Stimulation (TMS) and other therapies for patients with suicidal depression and related disorders [7]. - NRx Pharmaceuticals, the parent company of HOPE, is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [8]. Acquisition Details - Dura Medical, founded in 2018, specializes in a precision approach to treating mental health and chronic pain, offering services such as Ketamine Infusion Therapy and TMS [2][9]. - The acquisition is expected to provide comprehensive services to patients and is part of HOPE's strategy to expand its operations in Florida [1][9]. - The intended closing of the acquisition is subject to financial audits, regulatory approvals, and standard closing conditions [6]. Leadership and Mission - Stephen Durand, the founder of Dura Medical, will serve as the Director of Florida Clinic Operations for HOPE, emphasizing the mission to reduce suicide rates and treat over 10,000 individuals by 2026 [4][3]. - The collaboration aims to integrate Dura's commitment to patient care for both civilians and veterans into HOPE's network [5][9]. Services Offered - Dura Medical provides a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and TMS, catering to both veteran and civilian patients [9]. - The clinics utilize advanced interventional psychiatry procedures to address various mental health issues, including depression, suicidality, PTSD, and anxiety [2]. Future Plans - HOPE Therapeutics plans to expand its service offerings and enhance its operational capabilities through the acquisition of Dura Medical and the previously announced Neurospa network [1][9]. - The company is also pursuing the development of NRX-101, an investigational therapy for suicidal treatment-resistant bipolar depression, with plans to file for Accelerated Approval [8][10].